Thrombolysis after acute myocardial infarction: Are Canadian physicians up to the challenge?

CMAJ. Canadian Medical Association Journal

Volumn 156, Issue 4, 1997, Pages 509-511

  Williams, William L ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEALTH CARE ORGANIZATION; HUMAN;

EID: 0031056785     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
5. GISSI-Avoidable Delay Study Group. Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. Arch Intern Med 1995;155:1481-8.
6. Porter G, Doughty R, Gamble G, Sharpe N. Thrombolysis in acute myocardial infarction: reducing in hospital treatment delay. N Z Med J 1995;108:253-4.
7. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S, et al. As association between collateral flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992;327:1825-31.
8. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
9. The Heart and Stroke Foundation of Canada, the Canadian Cardiovascular Society and the Canadian Association of Emergency Physicians, for the Emergency Cardiac Care Coalition. Recommendations for ensuring early thrombolytic therapy for acute myocardial infarction. Can Med Asoc J 1996;154:483-7.